Skip to content
Company Analysis

10x Genomics, Inc. TXG

A comprehensive view of key metrics, scores, and financial health for 10x Genomics, Inc.

Overview of 10x Genomics, Inc.

TXG NMS
Healthcare Health Information Services Mid Cap
10x Genomics, Inc. (TXG), is a Mid Cap company, in the Health Information Services industry, last closed at $18.79, about 52.3% overvalued vs fair value, +74.6% 1Y return, placing in the top 25% of its sector.
$18.79
-0.79%
As of March 13, 2026
Previous close • Vol 90d: 70.5%
52-Week Range
Market Cap
$2.66B
Enterprise Value
$2.27B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for 10x Genomics, Inc..

Top Beats

Quick Facts

Website https://www.10xgenomics.com
HQ Pleasanton, CA
Employees 1,178
Fiscal year Dec 31

Next Events

Earnings May 7 Estimated

Fair Value Snapshot

Bear Base Bull
$8
$9
$10
Current: $18.79 -52% vs base

Engine Room Money Flow™

Mid Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$642.8M
5.2%%
Gross Profit
$443.9M
7.1%%
Operating Income
$-110.9M
43%%
Net Income
$-43.5M
76.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
-298.8%
Poor

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$21.2M
16.3% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating 10x Genomics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
60
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
63
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 89% Coverage
Trade-Off Triangle Visualization A ternary plot showing TXG's balance between Growth (33.9%), Profitability (34.6%), and Safety (31.4%). Growth 34% Safety 31% Profitability 35%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

59th percentile vs peers
60
Key Signals
Rev Growth YoY 5.2% 58p EPS Growth YoY 77.0% 73p Revenue CAGR 3Y 7.6% 51p
Strengths
  • Fcf Margin in top 20% of peers (20.2%, 90th percentile)
  • Current Ratio in top 20% of peers (4.46, 87th percentile)
  • Cash Flow To Debt Ratio in top 20% of peers (19.13, 93th percentile)
  • Quick Ratio in top 20% of peers (4.09, 87th percentile)
Risks

No significant risks identified for this axis.

Profitability

61th percentile vs peers
61
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

55th percentile vs peers
56
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for 10x Genomics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$8.96
- - -
-52.3% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info